Joris Diels

1.5k total citations
113 papers, 1.1k citations indexed

About

Joris Diels is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joris Diels has authored 113 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 34 papers in Oncology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joris Diels's work include Multiple Myeloma Research and Treatments (40 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Protein Degradation and Inhibitors (17 papers). Joris Diels is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Protein Degradation and Inhibitors (17 papers). Joris Diels collaborates with scholars based in Belgium, United States and United Kingdom. Joris Diels's co-authors include Suzy Van Sanden, Annette Lam, Jan Schadrack, Kasem S. Akhras, J.M. Olivares, Michael Povey, Zhongyun Zhao, Tetsuro Ito, Alice K. Jacobs and Shane Kavanagh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joris Diels

96 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joris Diels Belgium	19	224	218	216	209	186	113	1.1k
K. Thiele Germany	17	114 0.5×	173 0.8×	54 0.3×	225 1.1×	206 1.1×	56	1.5k
Ewald Wöll Austria	19	476 2.1×	535 2.5×	87 0.4×	109 0.5×	272 1.5×	56	1.3k
Ravi Potluri United States	13	77 0.3×	300 1.4×	64 0.3×	272 1.3×	196 1.1×	77	774
A.J. Lehman Canada	12	80 0.4×	81 0.4×	103 0.5×	225 1.1×	114 0.6×	30	1.2k
Paweł Hrycaj Poland	17	67 0.3×	176 0.8×	169 0.8×	223 1.1×	150 0.8×	75	2.1k
Mary Woods United Kingdom	14	116 0.5×	356 1.6×	49 0.2×	172 0.8×	64 0.3×	41	1.0k
Hege Sagstuen Haugnes Norway	22	455 2.0×	578 2.7×	45 0.2×	130 0.6×	421 2.3×	82	2.1k
Shinsuke Kojima Japan	18	196 0.9×	98 0.4×	73 0.3×	101 0.5×	167 0.9×	42	695
San‐Chi Chen Taiwan	16	167 0.7×	260 1.2×	47 0.2×	53 0.3×	128 0.7×	53	785
Andra Bălănescu Romania	18	47 0.2×	155 0.7×	91 0.4×	224 1.1×	117 0.6×	79	1.2k

Countries citing papers authored by Joris Diels

Since Specialization

Citations

This map shows the geographic impact of Joris Diels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joris Diels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joris Diels more than expected).

Fields of papers citing papers by Joris Diels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joris Diels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joris Diels. The network helps show where Joris Diels may publish in the future.

Co-authorship network of co-authors of Joris Diels

This figure shows the co-authorship network connecting the top 25 collaborators of Joris Diels. A scholar is included among the top collaborators of Joris Diels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joris Diels. Joris Diels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diels, Joris, et al.. (2026). Letter to the Editor Regarding: “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”. Oncology and Therapy. 14(1). 423–427.

Chouaïd, C., L. Bosquet, Craig Knott, et al.. (2025). Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 203. 108548–108548.

Rückert, Michael, Mamta Garg, Ceri Bygrave, et al.. (2024). Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network. Blood. 144(Supplement 1). 2388–2388.

Alsdorf, Winfried, Joris Diels, Francesca Ghilotti, et al.. (2024). Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of Comparative Effectiveness Research. 13(9). e240080–e240080. 3 indexed citations

Young, Allan H., Pierre‐Michel Llorca, Peter Falkai, et al.. (2024). Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. The British Journal of Psychiatry. 226(2). 72–78.

Špıčka, Ivan, Maximilian Merz, Jakub Radocha, et al.. (2023). P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK. HemaSphere. 7(S3). e258126d–e258126d. 2 indexed citations

Signorovitch, James, et al.. (2023). Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. Journal of Dermatological Treatment. 34(1). 2169574–2169574. 8 indexed citations

Girard, N., Joris Diels, Nora Rahhali, et al.. (2022). 19P Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis. Annals of Oncology. 33. S38–S38. 1 indexed citations

Martin, Tom, Saad Z. Usmani, Jordan M. Schecter, et al.. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion. 37(10). 1779–1788. 34 indexed citations

10.

Mesana, L., et al.. (2020). Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Current Medical Research and Opinion. 36(4). 595–606. 24 indexed citations

11.

McQuarrie, Kelly, et al.. (2018). Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study. Value in Health. 21. S38–S38. 3 indexed citations

12.

Sorensen, Sonja, Mark Wildgust, Nishan Sengupta, et al.. (2017). Indirect Treatment Comparisons of Ibrutinib Versus Physician’s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Clinical Therapeutics. 39(1). 178–189.e5. 7 indexed citations

13.

Saad, Fred, Tetsuro Ito, Joris Diels, et al.. (2017). Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer. Annals of Oncology. 28. v277–v277. 3 indexed citations

14.

Diels, Joris, Annette Lam, Tetsuro Ito, et al.. (2016). Indirect Comparison Of Daratumumab Monotherapy Versus Real-World Historical Control Data In Patients With Multiple Myeloma Who Are Heavily Pre-Treated And Highly Refractory. Value in Health. 19(3). A140–A140.

15.

Lange, Ansgar, et al.. (2015). Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML). Advances in Therapy. 32(9). 854–862. 8 indexed citations

16.

Diels, Joris & C. Neslusan. (2015). Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists. Value in Health. 18(3). A68–A69. 6 indexed citations

17.

Diels, Joris & Suzy Van Sanden. (2015). Bayesian Network Meta-Analysis To Assess Relative Efficacy Of Ibrutinib Versus Idelalisib+Ofatumumab And Physician’s Choice In Relapsed/Refractory Cll Patients. Value in Health. 18(7). A432–A432. 1 indexed citations

18.

Diels, Joris, et al.. (2014). The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value in Health. 17(7). A334–A334. 3 indexed citations

19.

Bitter, István, et al.. (2013). Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. European Neuropsychopharmacology. 23(11). 1383–1390. 29 indexed citations

20.

Arbyn, M., et al.. (1999). Incidence and prevalence of hysterectomy in the Flemish Region (Belgium). Ghent University Academic Bibliography (Ghent University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact